LEXICON PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
LEXICON PHARMACEUTICALS, INC. (LXRX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $153.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $153.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $123.10M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $2.50M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $16.30M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $153.70M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $123.10M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.50M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $16.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $76.40M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $57.30M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $12.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | $14.80M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $268.90M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $216.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $58.50M 10-K · filed 2025-03-07 |
| 2022-12-31 | $89.00M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |